Recently, immune checkpoint inhibitors (ICIs), such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies, have improved overall survival (OS) for various cancers including GC (6–10). This evidence concerns the gene CD274 and gastric cancer.